Interpharm Holdings Stock Analysis

Interpharm Stock Analysis Notes

The company recorded a loss per share of 0.09. Interpharm Holdings had not issued any dividends in recent years. The entity had 1:5 split on the 19th of November 1997. Interpharm Holdings, Inc. develops, manufactures, and markets generic prescription strength and over-the-counter pharmaceuticals. The company was founded in 1984 and is based in Hauppauge, New York. Interpharm Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 670 people. To learn more about Interpharm Holdings call the company at 631 952 0214.

Interpharm Holdings Investment Alerts

Interpharm Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.07 M.

Interpharm Profitablity

The company has Profit Margin (PM) of (0.42) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.24) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.24.

Management Efficiency

Interpharm Holdings has return on total asset (ROA) of (0.1853) % which means that it has lost $0.1853 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1707) %, meaning that it created substantial loss on money invested by shareholders. Interpharm Holdings' management efficiency ratios could be used to measure how well Interpharm Holdings manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.23. The Interpharm Holdings' current Return On Capital Employed is estimated to increase to -0.27. As of now, Interpharm Holdings' Intangibles To Total Assets are decreasing as compared to previous years. The Interpharm Holdings' current Debt To Assets is estimated to increase to 0.34, while Other Current Assets are projected to decrease to under 18 K.

Technical Drivers

Interpharm Holdings technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Interpharm Holdings Price Movement Analysis

Interpharm Holdings Financial Rating

Interpharm Holdings financial ratings play a critical role in determining how much Interpharm Holdings have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Interpharm Holdings' borrowing costs.

Interpharm Holdings Debt to Cash Allocation

Interpharm Holdings currently holds 12.06 M in liabilities with Debt to Equity (D/E) ratio of 3.43, implying the company greatly relies on financing operations through barrowing. Interpharm Holdings has a current ratio of 0.61, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Interpharm Holdings' use of debt, we should always consider it together with its cash and equity.

Interpharm Holdings Total Assets Over Time

Interpharm Holdings Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Interpharm Holdings uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Interpharm Holdings Debt Ratio

34.0

It feels like under 66% of Interpharm Holdings' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Interpharm Holdings' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Interpharm Holdings, which in turn will lower the firm's financial flexibility.

Interpharm Long Term Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Interpharm Holdings prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Interpharm shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Interpharm Holdings. By using and applying Interpharm Stock analysis, traders can create a robust methodology for identifying Interpharm entry and exit points for their positions.

When running Interpharm Holdings' price analysis, check to measure Interpharm Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Interpharm Holdings is operating at the current time. Most of Interpharm Holdings' value examination focuses on studying past and present price action to predict the probability of Interpharm Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Interpharm Holdings' price. Additionally, you may evaluate how the addition of Interpharm Holdings to your portfolios can decrease your overall portfolio volatility.